-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Pharmaceutical initiates China Phase II trial of albumin-bound sirolimus injection for epithelioid haemangioendothelioma

PUBT·07/16/2026 11:27:19
Listen to the news
CSPC Pharmaceutical initiates China Phase II trial of albumin-bound sirolimus injection for epithelioid haemangioendothelioma
  • CSPC initiated a multicenter Phase II trial in China for its albumin-bound sirolimus injection in progressive or symptomatic epithelioid haemangioendothelioma.
  • First site opened; recruitment and screening started for patients unsuitable for radical surgery who require systemic therapy.
  • Open-label, non-randomized design targets efficacy and safety readouts for the mTOR inhibitor, classified as a modified new chemical drug (Class 2.2).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12247193), on July 16, 2026, and is solely responsible for the information contained therein.